Alternative spliced variants as biomarkers of colorectal cancer

Current Drug Metabolism

Volumn 12, Issue 10, 2011, Pages 966-974

  Yi, Qian ^a   Tang, Liling ^a  

^a CHONGQING UNIVERSITY   (China)

Author keywords

Alternative spliced variants; Alternative splicing; Biomarker; Colorectal cancer; Diagnosis; Prognosis

Indexed keywords

APC PROTEIN; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; EDRECOLOMAB; FLICE INHIBITORY PROTEIN; FLUOROURACIL; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN A;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; DYSLEXIA; HUMAN; NONSENSE MEDIATED MRNA DECAY; PROTEIN BLOOD LEVEL; RNA SPLICING;

ALTERNATIVE SPLICING; COLORECTAL NEOPLASMS; HUMANS; PROTEIN ISOFORMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 82255195536     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011798062355     Document Type: Article

References (107)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E.. Cancer Statistics, 2010. CA Cancer J. Clin., 2010, 60(5), 277-300.
2. Venables, J. P.; Klinck, R.; Bramard, A.; Inkel, L.; Dufresne-Martin, G.; Koh, C.; Gervais-Bird, J.; Lapointe, E.; Froehlich, U.; Durand, M.; Gendron, D.; Brosseau, J. P.; Thibault, P.; Lucier, J. F.; Tremblay, K.; Prinos, P.; Wellinger, R. J.; Chabot, B.; Rancourt, C.; Elela, S. A.. Identification of Alternative Splicing Markers for Breast Cancer. Cancer Res., 2008, 68(22), 9525-9531.
3. Klinck, R.; Bramard, A.; Inkel, L.; Dufresne-Martin, G.; Gervais-Bird, J.; Madden, R.; Paquet, E. R.; Koh, C.; Venables, J. P.; Prinos, P.; Jilaveanu-Pelmus, M.; Wellinger, R.; Rancourt, C.; Chabot, B.; Abou Elela, S.. Multiple Alternative Splicing Markers for Ovarian Cancer. Cancer Res., 2008, 68(3), 657-663. (Pubitemid 351206740)
4. Thorsen, K.; Sørensen, K. D.; Brems-Eskildsen, A. S.; Modin, C.; Gaustadnes, M.; Hein, A. M.; Kruhøffer, M.; Laurberg, S.; Borre, M.; Wang, K.; Brunak, S.; Krainer, A. R.; Tørring, N.; Dyrskjøt, L.; Andersen, C. L.; Orntoft, T. F.. Alternative Splicing in Colon, Bladder, and Prostate Cancer Identified by Exon Array Analysis. Mol. Cell Proteomics, 2008, 7(7), 1214-1224. (Pubitemid 352038268)
5. Schmucker, D.; Clemens, J. C.; Shu, H.; Worby, C. A.; Xiao, J.; Muda, M.; Dixon, J. E.; Zipursky, S. L.. Drosophila Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity. Cell, 2000, 101(6), 671-684.
6. Bark, I. C.; Wilson, M. C.. Human cDNA clones encoding two different isoforms of the nerve terminal protein SNAP-25. Gene, 1994, 139(2), 291-292. (Pubitemid 24078740)
7. Sørensen, J. B.; Nagy, G.; Varoqueaux, F.; Nehring, R. B.; Brose, N.; Wilson, M. C.; Neher, E.. Differential control of the releasable vesicle pools by SNAP-25 splice variants and SNAP-23. Cell, 2003, 114(1), 75-86. (Pubitemid 36859842)
8. Black, D. L.. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem., 2003, 72, 291-336. (Pubitemid 36930448)
9. Graveley, B. R.. Sorting out the complexity of SR protein functions. RNA, 2000, 6(9), 1197-1211.
10. Martinez-Contreras, R.; Cloutier, P.; Shkreta, L.; Fisette, J. F.; Revil, T.; Chabot, B.. hnRNP proteins and splicing control. Adv. Exp. Med. Biol., 2007, 623, 123-147.
11. Cowper, A. E.; Cáceres, J. F.; Mayeda, A.; Screaton, G. R.. Serinearginine (SR) protein-like factors that antagonize authentic SR proteins and regulate alternative splicing. J. Biol. Chem., 2001, 276(52), 48908-48914.
12. Martinez-Contreras, R.; Fisette, J. F.; Nasim, F. U.; Madden, R.; Cordeau, M.; Chabot, B.. Intronic binding sites for hnRNP A/B and hnRNP F/H proteins stimulate pre-mRNA splicing. PLoS Biol., 2006, 4(2), 21.
13. Libri, D.; Piseri, A.; Fiszman, M. Y.. Tissue-specific splicing in vivo of the beta-tropomyosin gene: dependence on an RNA secondary structure. Science, 1991, 252(5014), 1842-1845. (Pubitemid 21917107)
14. Kornblihtt, A. R.. Chromatin, transcript elongation and alternative splicing. Nat. Struct. Mol. Biol., 2006, 13(1), 5-7. (Pubitemid 43049394)
15. Houseley, J.; Tollervey, D.. The Many Pathways of RNA Degradation. Cell, 2009, 136(4), 763-776.
16. Johnson, J. M.; Castle, J.; Garrett-Engele, P.; Kan, Z.; Loerch, P. M.; Armour, C. D.; Santos, R.; Schadt, E. E.; Stoughton, R.; Shoemaker, D, D. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science, 2003, 302(5653), 2141-2144. (Pubitemid 38017950)
17. Peters, D. J.; Sandkuijl, L. A.. Genetic heterogeneity of polycystic kidney disease in Europe. Contrib. Nephrol., 1992, 97, 128-139.
18. Hayashi, T.; Mochizuki, T.; Reynolds, D. M.; Wu, G.; Cai, Y.; Somlo, S.. Characterization of the exon structure of the polycystic kidney disease2 gene (PKD2). Genomics, 1997, 44(1), 131-136. (Pubitemid 27383348)
19. Tan, Y. C.; Blumenfeld, J.; Michaeel, A.; Donahue, S.; Balina, M.; Parker, T.; Levine, D.; Rennert, H.. Aberrant PKD2 splicing due to a presumed novel missense mutation in autosomal-dominant polycystic kidney disease. Clin. Genet., 2010. [Epub ahead of print].
20. Cartegni, L.; Chew, S. L.; Krainer, A. R.. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet., 2002, 3(4), 285-298. (Pubitemid 34279797)
21. Faustino, N. A., Cooper, T. A.. Pre-mRNA splicing and human disease. Genes Dev., 2003, 17(4), 419-437. (Pubitemid 36258756)
22. Dobrowolski, S. F.; Andersen, H. S.; Doktor, T. K.; Andresen, B. S.. The phenylalanine hydroxylase c.30C
23. Ikezawa, M.; Nishino, I.; Goto, Y.; Miike, T.; Nonaka, I.. Newly recognized exons induced by a splicing abnormality from an intronic mutation of the dystrophin gene resulting in Duchenne muscular dystrophy. Hum. Mutat., 1999, 13(2), 170.
24. Kulseth, M. A.; Berge, K. E.; Bogsrud, M. P.; Leren, T. P.. Analysis of LDLR mRNA in patients with familial hypercholesterolemia revealed a novel mutation in intron 14, which activates a cryptic splice site. J. Hum. Genet., 2010, 55(10), 676-680.
25. Anthony, K.; Gallo, J. M.. Aberrant RNA processing events in neurological disorders. Brain Res., 2010, 1338, 67-77.
26. Yang, L.; Hui, W. S.; Chan, W. C.; Ng, V. C.; Yam, T. H.; Leung, H. C.; Huang, J. D.; Shum, D. K.; Jie, Q.; Cheung, K. M.; Cheah, K. S.; Luo, Z.; Chan, D.. A splice-site mutation leads to haploinsufficiency of EXT2 mRNA for a dominant trait in a large family with multiple osteochondromas. J. Orthop. Res., 2010, 28(11), 1522-1530.
27. Wagoner, M. P.; Gunsalus, K. T.; Schoenike, B.; Richardson, A. L.; Friedl, A.; Roopra, A.. The Transcription Factor REST Is Lost in Aggressive Breast Cancer. PLoS Genetics, 2010, 6(6), 1000979.
28. Dehm, S. M.; Schmidt, L. J.; Heemers, H. V.; Vessella, R. L.; Tindall, D. J.. Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance. Cancer Res., 2008, 68(13), 5469-5477.
29. Oliveira, C.; Senz, J.; Kaurah, P.; Pinheiro, H.; Sanges, R.; Haegert, A.; Corso, G.; Schouten, J.; Fitzgerald, R.; Vogelsang, H.; Keller, G.; Dwerryhouse, S.; Grimmer, D.; Chin, S. F.; Yang, H. K.; Jackson, C. E.; Seruca, R.; Roviello, F.; Stupka, E.; Caldas, C.; Huntsman, D.. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum. Mol. Genet., 2009, 18(9), 1545-1555.
30. Matsukuma, K. E.; Mullins, F. M.; Dietz, L.; Zehnder, J. L.; Ford, J. M.; Chun, N. M.; Schrijver, I.. Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation. Hum. Pathol., 2010, 41(8), 1200-1203.
31. Hiller, M.; Huse, K.; Szafranski, K.; Jahn, N.; Hampe, J.; Schreiber, S.; Backofen, R.; Platzer, M.. Widespread occurrence of alternative splicing at NAGNAG acceptors contributes to proteome plasticity. Nat. Genet., 2004, 36(12), 1255-1257. (Pubitemid 39577932)
32. Hiller, M.; Platzer, M.. Widespread and subtle: alternative splicing at short-distance tandem sites. Trends Genet., 2008, 24, 246-255.
33. Vitale, L.; Frabetti, F.; Huntsman, S. A.; Canaider, S.; Casadei, R.; Lenzi, L.; Facchin, F.; Carinci, P.; Zannotti, M.; Coppola, D.; Strippoli, P.. Sequence, "subtle" alternative splicing and expression of the CYYR (cysteine/tyrosine-rich 1) mRNA in human neuroendocrine tumors. BMC Cancer., 2007, 7, 66.
34. Hiller, M.; Huse, K.; Szafranski, K.; Jahn, N.; Hampe, J.; Schreiber, S.; Backofen, R.; Platzer, M.. Single-Nucleotide Polymorphisms in NAGNAG Acceptors Are Highly Predictive for Variations of Alternative Splicing. Am. J. Hum. Genet., 2006, 78(2), 291-302. (Pubitemid 43157568)
35. Walker, L. C.; Whiley, P. J.; Couch, F. J.; Farrugia, D. J.; Healey, S.; Eccles, D. M.; Lin, F.; Butler, S. A.; Goff, S. A.; Thompson, B. A.; Lakhani, S. R.; Da Silva, L. M.; Tavtigian, S. V.; Goldgar, D. E.; Brown, M. A.; Spurdle, A. B.. Detection of Splicing Aberrations Caused by BRCA1 and BRCA2 Sequence Variants Encoding Missense Substitutions: Implications for Prediction of Pathogenicity. Hum. Mutat., 2010, 31(6), 1484-1505.
36. Nielsen, K. B.; Sørensen, S.; Cartegni, L.; Corydon, T. J.; Doktor, T. K.; Schroeder, L. D.; Reinert, L. S.; Elpeleg, O.; Krainer, A. R.; Gregersen, N.; Kjems, J.; Andresen, B. S.. Seemingly Neutral Polymorphic Variants May Confer Immunity to Splicing-Inactivating Mutations: A Synonymous SNP in Exon 5 of MCAD Protects from Deleterious Mutations in a Flanking Exonic Splicing Enhancer. Am. J. Hum. Genet., 2007, 80(3), 416-432.
37. López-Saavedra, A.; Herrera, L. A.. The role of alternative mRNA splicing in chromosome instability. Mutat. Res., 2010, 705(3), 246-251.
38. Venables, J. P.. Aberrant and Alternative Splicing in Cancer. Cancer Res., 2004, 64(21), 7647-7654. (Pubitemid 39446889)
39. Winawer, S. J. Colorectal cancer screening. Best Practice & Research Clinical Gastroenterology, 2007, 21(6), 1031-1048. (Pubitemid 350215368)
40. Huerta, S. Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Rev. Mol. Diagn., 2008, 8(3), 277-288. (Pubitemid 351724707)
41. Groden, J.; Thliveris, A.; Samowitz, W.; Carlson, M.; Gelbert, L.; Albertsen, H.; Joslyn, G.; Stevens, J.; Spirio, L.; Robertson, M.. Identification and characterization of the familial adenomatous polyposis coli gene. Cell, 1991, 66(3), 589-600.
42. Friedl, W.; Meuschel, S.; Caspari, R.; Lamberti, C.; Krieger, S.; Sengteller, M.; Propping, P.. Attenuated familial adenomatous polyposis due to a mutation in the 3¢ part of the APC gene. A clue for understanding the function of the APC protein. Hum. Genet., 1996, 97(5), 579-584.
43. Fodde, R.. The APC gene in colorectal cancer. Eur J Cancer, 2002;38(7):867-871. (Pubitemid 34442313)
44. Su, L. K.; Vogelstein, B.; Kinzler, K. W.. Association of the APC tumor suppressor protein with catenins. Science, 1993, 262(5140), 1734-1737. (Pubitemid 24030097)
45. Rubinfeld, B.; Souza, B.; Albert, I.; Müller, O.; Chamberlain, S. H.; Masiarz, F. R.; Munemitsu, S.; Polakis, P.. Association of the APC gene product with beta-catenin. Science, 1993, 262(5140), 1731-1734. (Pubitemid 24030096)
46. Carson, D. J.; Santoro, I. M.; Groden, J.. Isoforms of the APC tumor suppressor and their ability to inhibit cell growth and tumorigenicity. Oncogene, 2004, 23(42), 7144-7148. (Pubitemid 39319176)
47. Munemitsu, S.; Souza, B.; Müller, O.; Albert, I.; Rubinfeld, B.; Polakis, P.. The APC gene product associates with microtubules in vivo and promotes their assembly in vitro. Cancer Res., 1994, 54(14), 3676-3681. (Pubitemid 24241177)
48. Kaplan, K. B.; Burds, A. A.; Swedlow, J. R.; Bekir, S. S.; Sorger, P. K.; Näthke, I. S.. A role for the adenomatous polyposis coli protein in chromosome segregation. Nat. Cell Biol., 2001, 3(4), 429-432. (Pubitemid 32288453)
49. Morin, P. J.; Vogelstein, B.; Kinzler, K. W.. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. U S A., 1996, 93(15), 7950-7954. (Pubitemid 26277145)
50. Spirio, L.; Green, J.; Robertson, J.; Robertson, M.; Otterud, B.; Sheldon, J.; Howse, E.; Green, R.; Groden, J.; White, R.; Leppert, M.. The identical 5' splice-site acceptor mutation in five attenuated APC families from Newfoundland demonstrates a founder effect. Hum. Genet., 1999, 105(5), 388-398.
51. Varesco, L.; Gismondi, V.; Presciuttini, S.; Groden, J.; Spirio, L.; Sala, P.; Rossetti, C.; De Benedetti, L.; Bafico, A.; Heouaine, A.. Mutation in a splice-donor site of the APC gene in a family with polyposis and late age of colonic cancer death. Hum. Genet., 1994, 93(3), 281-286. (Pubitemid 24066928)
52. Tuohy, T. M.; Done, M. W.; Lewandowski, M. S.; Shires, P. M.; Saraiya, D. S.; Huang, S. C.; Neklason, D. W.; Burt, R. W.. Large intron 14 rearrangement in APC results in splice defect and attenuated FAP. Hum. Genet., 2010, 127(3), 359-369.
53. Fostira, F.; Yannoukakos, D.. A distinct mutation on the alternative splice site of APC exon 9 results in attenuated familial adenomatous polyposis phenotype. Fam. Cancer, 2010, 9(3), 395-400.
54. De Rosa, M.; Morelli, G.; Cesaro, E.; Duraturo, F.; Turano, M.; Rossi, G. B.; Delrio, P.; Izzo, P.. Alternative splicing and nonsensemediated mRNA decay in the regulation of a new adenomatous polyposis coli transcript. Gene, 2007, 395(1-2), 8-14. (Pubitemid 46670630)
55. Løvig, T.; Meling, G. I.; Diep, C. B.; Thorstensen, L.; Norheim Andersen, S.; Lothe, R. A.; Rognum, T. O.. APC and CTNNB1 mutations in a large series of sporadic colorectal carcinomas stratified by the microsatellite instability status. Scand. J. Gastroenterol., 2002, 37(10), 1184-1193. (Pubitemid 35178685)
56. Charames, G. S.; Cheng, H.; Gilpin, C. A.; Hunter, A. G.; Berk, T.; Bapat, B.. A novel aberrant splice site mutation in the APC gene. J. Med. Genet., 2002, 39(10), 754-757. (Pubitemid 35178727)
57. Aretz, S.; Uhlhaas, S.; Sun, Y.; Pagenstecher, C.; Mangold, E.; Caspari, R.; Möslein, G.; Schulmann, K.; Propping, P.; Friedl, W.. Familial Adenomatous Polyposis: Aberrant Splicing Due to Missense or Silent Mutations in the APC. Hum. Mutat., 2004, 24(5), 370-380. (Pubitemid 39473662)
58. Gonçalves, V.; Theisen, P.; Antunes, O.; Medeira, A.; Ramos, J. S.; Jordan, P.; Isidro, G.. A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14. Mutation Research, 2009, 662(1-2), 33-36.
59. Westbrook, C. A.; Gasson, J. C.; Gerber, S. E.; Selsted, M. E.; Golde, D. W.. Purification and characterization of human T-lymphocytederived erythroid-potentiating activity. J. Biol. Chem., 1984, 259(16), 9992-9996. (Pubitemid 14067665)
60. Guedez, L.; Courtemanch, L.; Stetler-Stevenson, M.. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood, 1998, 92(4), 1342-1349. (Pubitemid 28369048)
61. Liu, X. W.; Bernardo, M. M.; Fridman, R.; Kim, H. R.. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J. Biol. Chem., 2003, 278(41), 40364-40372. (Pubitemid 37248605)
62. Akahane, T.; Akahane, M.; Shah, A.; Connor, C. M.; Thorgeirsson, U. P.. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp. Cell Res., 2004, 301(2), 158-167. (Pubitemid 39504969)
63. Holten-Andersen, M. N.; Christensen, I. J.; Nielsen, H. J.; Stephens, R. W.; Jensen, V.; Nielsen, O. H.; Sørensen, S.; Overgaard, J.; Lilja, H.; Harris, A.; Murphy, G.; Brünner, N.. Total Levels of Tissue Inhibitor of Metalloproteinases 1 in Plasma Yield High Diagnostic Sensitivity and Specificity in Patients with Colon Cancer. Clin. Cancer Res., 2002, 8(1), 156-164. (Pubitemid 34101472)
64. Pellegrini, P.; Contasta, I.; Berghella, A. M; Gargano, E.; Mammarella, C.; Adorno, D.. Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer. Cancer Immunol. Immunother., 2000, 49(7), 388-394.
65. Sørensen, N. M.; Byström, P.; Christensen, I. J.; Berglund, A.; Nielsen, H. J.; Brünner, N.; Glimelius, B.. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin. Cancer Res., 2007, 13(14), 4117-4122. (Pubitemid 47105974)
66. Inagaki, D.; Oshima, T.; Yoshihara, K.; Tamura, S.; Kanazawa, A.; Yamada, T.; Yamamoto, N.; Sato, T.; Shiozawa, M.; Morinaga, S.; Akaike, M.; Fujii, S.; Numata, K.; Kunisaki, C.; Rino, Y.; Tanaka, K.; Masuda, M.; Imada, T.. Overexpression of tissue inhibitor of metalloproteinase-1 gene correlates with poor outcomes in colorectal cancer. Anticancer Res., 2010, 30(10), 4127-4130.
67. Usher, P. A.; Sieuwerts, A. M.; Bartels, A.; Lademann, U.; Nielsen, H. J.; Holten-Andersen, L.; Foekens, J. A.; Brünner, N.; Offenberg, H.. Identification of alternatively spliced TIMP-1 mRNA in cancer cell lines and colon cancer tissue. Mol. Oncol., 2007, 1(2), 205-215. (Pubitemid 47199133)
68. Leung, D. W.; Cachianes, G.; Kuang, W. J.; Goeddel, D. V.; Ferrara, N.. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989, 246(4935), 1306-1309. (Pubitemid 20066716)
69. Senger, D. R.; Galli, S. J.; Dvorak, A. M.; Perruzzi, C. A.; Harvey, V. S.; Dvorak, H. F.. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 219, 983-985.
70. Takahashi, Y.; Kitadai, Y.; Bucana, C. D.; Cleary, K. R.; Ellis, L. M.. Expression of Vascular Endothelial Growth Factor and Its Receptor, KDR, Correlates with Vascularity, Metastasis, and Proliferation of Human Colon Cancer. Cancer Res., 1995, 55(18), 3964-3968.
71. Tischer, E.; Mitchell, R.; Hartman, T.; Silva, M.; Gospodarowicz, D.; Fiddes, J. C.; Abraham, J. A.. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem., 1991, 266(18), 11947-11954.
72. Bates, D. O.; Cui, T. G.; Doughty, J. M.; Winkler, M.; Sugiono, M.; Shields, J. D.; Peat, D.; Gillatt, D.; Harper, S. J.. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is downregulated in renal cell carcinoma. Cancer Res., 2002, 62(14), 4123-4131. (Pubitemid 34791084)
73. Houck, K. A.; Ferrara, N.; Winer, J.; Cachianes, G.; Li, B.; Leung, D. W.. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol., 1991, 5(12), 1806-1814.
74. Kumar, H.; Heer, K.; Lee, P. W.; Duthie, G. S.; MacDonald, A. W.; Greenman, J.; Kerin, M. J.; Monson, J. R.. Preoperative Serum Vascular Endothelial Growth Factor Can Predict Stage in Colorectal Cancer. Clin. Cancer Res., 1998, 4(5), 1279-1285. (Pubitemid 28213341)
75. Karayiannakis, A. J.; Syrigos, K. N.; Zbar, A.; Baibas, N.; Polychronidis, A.; Simopoulos, C.; Karatzas. G.. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery, 2002, 131(5), 548-555. (Pubitemid 34478504)
76. Poon, R. T.; Lau, C. P.; Cheung, S. T.; Yu, W. C.; Fan, S. T.. Quantitative Correlation of Serum Levels and Tumor Expression of Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma. Cancer Res., 2003, 63(12), 3121-3126. (Pubitemid 36735862)
77. Hawinkels, L. J.; Zuidwijk, K.; Verspaget, H. W.; de Jonge-Muller, E. S.; van Duijn, W.; Ferreira, V.; Fontijn, R. D.; David, G.; Hommes, D. W.; Lamers, C. B.; Sier, C. F.. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur. J. Cancer., 2008, 44(13), 1904-1913.
78. Díaz, R.; Peña, C.; Silva, J.; Lorenzo, Y.; García, V.; García, J. M.; Sánchez, A.; Espinosa, P.; Yuste, R.; Bonilla, F.; Domínguez, G.. p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int. J. Cancer., 2008, 123(5), 1060-1067.
79. Taipale, M.; Kaminen, N.; Nopola-Hemmi, J.; Haltia, T.; Myllyluoma, B.; Lyytinen, H.; Muller, K.; Kaaranen, M.; Lindsberg, P. J.; Hannula-Jouppi, K.; Kere, J.. A candidate gene for developmental dyslexia encodes a nuclear tetratricopeptide repeat domain protein dynamically regulated in brain. Proc. Natl. Acad. Sci. U S A., 2003, 100(20), 11553-11558. (Pubitemid 37205974)
80. Dahdouh, F.; Anthoni, H.; Tapia-Páez, I.; Peyrard-Janvid, M.; Schulte-Körne, G.; Warnke, A.; Remschmidt, H,; Ziegler, A.; Kere, J.; Müller-Myhsok, B.; Nöthen, M. M.; Schumacher, J.; Zucchelli, M.. Further evidence for DYX1C1 as a susceptibility factor for dyslexia. Psychiatr. Geneti., 2009, 19(2), 59-63.
81. Wang, Y.; Paramasivam, M.; Thomas, A.; Bai, J.; Kaminen-Ahola, N.; Kere, J.; Voskuil, J.; Rosen, G. D.; Galaburda, A. M.; Loturco, J. J.. DYX1C1 functions in neuronal migration in developing neocortex. Neuroscience, 2006, 143(2), 515-522. (Pubitemid 44781065)
82. Chen, Y.; Zhao, M.; Wang, S.; Chen, J.; Wang, Y.; Cao, Q.; Zhou, W.; Liu, J.; Xu, Z.; Tong, G.; Li, J.. A novel role for DYX1C1, a chaperone protein for both Hsp70 and Hsp90, in breast cancer. J. Cancer Res. Clin. Oncol., 2009, 135(9), 1265-1276.
83. Kim, Y. J.; Huh, J. W.; Kim, D. S.; Bae, M. I.; Lee, J. R.; Ha, H. S.; Ahn, K.; Kim, T. O.; Song, G. A.; Kim, H. S.. Molecular characterization of the DYX1C1 gene and its application as a cancer biomarker. J. Cancer Res. Clin. Oncol., 2009, 135(2), 265-270.
84. Kim, K.; Fisher, M. J.; Xu, S. Q.; el-Deiry, W. S.. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res., 2000, 6(2), 335-46. (Pubitemid 30111448)
85. McLornan, D. P.; Barrett, H. L.; Cummins, R.; McDermott, U.; McDowell, C.; Conlon, S. J.; Coyle, V. M.; Van Schaeybroeck, S.; Wilson, R.; Kay, E. W.; Longley, D. B.; Johnston, P. G.. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin. Cancer Res., 2010, 16(13), 3442-3451.
86. Ryu, B. K.; Lee, M. G.; Chi, S. G.; Kim, Y. W.; Park, J. H.. Increased expression of cFLIP (L) in colonic adenocarcinoma. J. Pathol., 2001, 194(1), 15-9.
87. Zang, F.; Sun, B.; Zhao, X.; Niu, R.; Zhang, S.; Yu, M.; Wei, X.; Zhang, L.. Critical role for c-FLIP (L) on Fas resistance in colon carcinoma cell line HT-29. Cell Biol. Int., 2008, 32(3), 329-336.
88. Ullenhag, G. J.; Mukherjee, A.; Watson, N. F.; Al-Attar, A. H.; Scholefield, J. H.; Durrant, L. G.. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin. Cancer Res., 2007, 13(17), 5070-5075. (Pubitemid 47502072)
89. Varey, A.; Rennel, E.; Qiu, Y.; Bevan, H.; Perrin, R.; Raffy, S.; Dixon, A.; Paraskeva, C.; Zaccheo, O.; Hassan; Harper, S.; Bates, D.. VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy. Br. J. Cancer., 2008, 98(8), 1366-1379. (Pubitemid 351543576)
90. Ullenhag, G. J.; Mukherjee, A.; Watson, N. F.; Al-Attar, A. H.; Scholefield, J. H.; Durrant, L. G.. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin. Cancer Res., 2007, 13(17), 5070-5075. (Pubitemid 47502072)
91. Longley, D. B.; Wilson, T. R.; McEwan, M.; Allen, W. L.; McDermott, U.; Galligan, L.; Johnston, P. G.. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene, 2006, 25(6), 838-848. (Pubitemid 43237702)
92. Wilson, T. R.; McLaughlin, K. M.; McEwan, M.; Sakai, H.; Rogers, K. M.; Redmond, K. M.; Johnston, P. G.; Longley, D. B.. c-FLIP: A Key Regulator of Colorectal Cancer Cell Death. Cancer Res., 2007, 67(12), 5754-5762. (Pubitemid 46985008)
93. Tsuruma, T.; Hata, F.; Torigoe, T.; Furuhata, T.; Idenoue, S.; Kurotaki, T.; Yamamoto, M.; Yagihashi, A.; Ohmura, T.; Yamaguchi, K.; Katsuramaki, T.; Yasoshima, T.; Sasaki, K.; Mizushima, Y.; Minamida, H.; Kimura, H.; Akiyama, M.; Hirohashi, Y.; Asanuma, H.; Tamura, Y.; Shimozawa, K.; Sato, N.; Hirata, K.. Phase I clinical study of anti-apoptosis protein, survivinderived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Transl. Med., 2004, 2(1), 19.
94. Sawai, K.; Goi, T.; Hirono, Y.; Katayama, K.; Yamaguchi, A.. Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil. Oncol Res., 2010, 18(11-12), 541-547.
95. Wu, D.; Matsushita, K.; Matsubara, H.; Nomura, F.; Tomonaga, T.. An alternative splicing isoform of eukaryotic initiation factor 4H promotes tumorigenesis in vivo and is a potential therapeutic target for human cancer. Int. J. Cancer., 2010. [Epub ahead of print]
96. *0101 allele in the colorectal cell line HCA-7. Tissue Antigens., 2005, 66(3), 231-237. (Pubitemid 41243311)
97. Ikeuchi, K.; Marusawa, H.; Fujiwara, M.; Matsumoto, Y.; Endo, Y.; Watanabe, T.; Iwai, A.; Sakai, Y.; Takahashi, R.; Chiba, T.. Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers. Int. J. Cancer., 2009, 125(9), 2029-2035.
98. Horváth, H. C.; Khabir, Z.; Nittke, T.; Gruber, S.; Speer, G.; Manhardt, T.; Bonner, E.; Kallay, E.. CYP24A1 splice variants-Implications for the antitumorigenic actions of 1, 25-(OH) 2D3 in colorectal cancer. J. Steroid Biochem. Mol. Biol., 2010, 121(1-2), 76-79.
99. Aust, G.; Hamann, J.; Schilling, N.; Wobus, M.. Detection of alternatively spliced EMR2 mRNAs in colorectal tumor cell lines but rare expression of the molecule in colorectal adenocarcinomas. Virchows Arch., 2003, 443(1), 32-37. (Pubitemid 36920948)
100. Selzer-Plon, J.; Bornholdt, J.; Friis, S.; Bisgaard, H. C.; Lothe, I. M.; Tveit, K. M.; Kure, E. H.; Vogel, U.; Vogel, L. K.. Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis. BMC Cancer., 2009, 9, 201.
101. Willis, N. D.; Cox, T. R.; Rahman-Casañs, S. F.; Smits, K.; Przyborski, S. A.; van den Brandt, P.; van Engeland, M.; Weijenberg, M.; Wilson, R. G.; de Bruïne, A.; Hutchison, C. J.. Lamin A/C Is a Risk Biomarker in Colorectal Cancer. PLoS ONE., 2008, 3(8), 2988.
102. Rennel, E. S.; Varey, A. H.; Churchill, A. J.; Wheatley, E. R.; Stewart, L.; Mather, S.; Bates, D. O.; Harper, S. J.. VEGF121b, a new member of the VEGFxxxb family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo. Bri. J. Cancer., 2009, 101(7), 1183-1193.
103. Duval, A.; Rolland, S.; Tubacher, E.; Bui, H.; Thomas, G.; Hamelin, R.. The Human T-Cell Transcription Factor-4 Gene: Structure, Extensive Characterization of Alternative Splicings, and Mutational Analysis in Colorectal Cancer Cell Lines. Cancer Res., 2000, 60(14), 3872-3879. (Pubitemid 32204580)
104. Na IK; Busse A; Scheibenbogen C; Ghadjar P; Coupland SE; Letsch A; Loddenkemper C; Stroux A; Bauer S; Thiel E; Keilholz U. Identification of truncated chemokine receptor 7 in human colorectal cancer unable to localize to the cell surface and unreactive to external ligands. Int. J. Cancer., 2008, 123(7), 1565-1572.
105. Matsushita, K.; Kajiwara, T.; Itoga, S.; Satoh, M.; Sogawa, K.; Umemura, H.; Sawai, S.; Nishimura, M.; Tamura, M.; Tanaka, N.; Shimada, H.; Tomonaga, T.; Nomura, F.. Clinical application of alternative splicing form of c-myc suppressor FUSE-binding proteininteracting repressor for cancer detection and treatment. Rinsho Byori., 2009, 57(12), 1151-1158.
106. Gonçalves, V.; Matos, P.; Jordan, P.. Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Hum. Mol. Genet., 2009, 18(19), 3696-3707.
107. Tanaka, M.; Tanaka, T.; Kijima, H.; Itoh, J.; Matsuda, T.; Hori, S.; Yamamoto, M.. Characterization of tissue-and cell-type-specific expression of a novel human septin family gene, Bradeion. Biochem. Biophys. Res. Commun., 2001, 286(3), 547-553. (Pubitemid 32912981)